Home
|
Help
|
Contact
Sign in
WPRIM Management System>
DCMS
>
Journal of Gynecologic Oncology
>
>
23
>
4
Volume:
23
Issue:
4
1. Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration.
Page:274—281
2. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer.
Page:265—273
3. Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration.
Page:274—281
4. Risk factors for recurrence amongst high intermediate risk patients with endometrioid adenocarcinoma.
Page:257—264
5. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer.
Page:265—273
6. How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study.
Page:251—256
7. Risk factors for recurrence amongst high intermediate risk patients with endometrioid adenocarcinoma.
Page:257—264
8. Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea.
Page:242—250
9. How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study.
Page:251—256
10. Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer.
Page:235—241
11. Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea.
Page:242—250
12. Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer.
Page:226—234
13. Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer.
Page:235—241
14. Early human papillomavirus testing predicts residual/recurrent disease after LEEP.
Page:217—225
15. Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer.
Page:226—234
16. TGCS's Annual Meeting, August 10-12, 2012.
Page:215—216
17. Early human papillomavirus testing predicts residual/recurrent disease after LEEP.
Page:217—225
18. Combat against cervical cancer-challenges in Asia Oceania: 5th Biennial Conference of the Asia Oceania Research Organization on Genital Infections & Neoplasia (AOGIN).
Page:213—214
19. TGCS's Annual Meeting, August 10-12, 2012.
Page:215—216
20. Emerging concept of tailored lymphadenectomy in endometrial cancer.
Page:210—212
21. Combat against cervical cancer-challenges in Asia Oceania: 5th Biennial Conference of the Asia Oceania Research Organization on Genital Infections & Neoplasia (AOGIN).
Page:213—214
22. Optimal therapy for IB2 and IIA2 cervical cancer: surgery or chemoradiotherapy?.
Page:207—209
23. Emerging concept of tailored lymphadenectomy in endometrial cancer.
Page:210—212
24. Optimal therapy for IB2 and IIA2 cervical cancer: surgery or chemoradiotherapy?.
Page:207—209
25. Book Review: The emperor of all maladies: a biography of cancer.
Page:291—292
26. Sweet's syndrome: a cutaneous harbinger of ovarian carcinoma.
Page:288—290
27. New insights into cervical cancer screening.
Page:282—287